Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies

• Published in: Cancers 2010-05, Vol.2 (2), p.913-954
• Main Authors: Le Page, Cécile, Huntsman, David G, Provencher, Diane M, Mes-Masson, Anne-Marie
• Format: Article
• Language: English
• Subjects: Ovarian cancer; Review
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers2020913

Epithelial ovarian cancer is the most lethal gynecological malignancy. Due to its lack of symptoms, this disease is diagnosed at an advanced stage when the cancer has already spread to secondary sites. While initial rates of response to first treatment is >80%, the overall survival rate of patients is extremely low, mainly due to development of drug resistance. To date, there are no reliable clinical factors that can properly stratify patients for suitable chemotherapy strategies. Clinical parameters such as disease stage, tumor grade and residual disease, although helpful in the management of patients after their initial surgery to establish the first line of treatment, are not efficient enough. Accordingly, reliable markers that are independent and complementary to clinical parameters are needed for a better management of these patients. For several years, efforts to identify prognostic factors have focused on molecular markers, with a large number having been investigated. This review aims to present a summary of the recent advances in the identification of molecular biomarkers in ovarian cancer patient tissues, as well as an overview of the need and importance of molecular markers for personalized medicine in ovarian cancer.